KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Assets: 2017-2024

Historic Current Assets for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $1.6 billion.

  • Amneal Pharmaceuticals' Current Assets rose 21.49% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 21.49%. This contributed to the annual value of $1.6 billion for FY2024, which is 15.24% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Current Assets stood at $1.6 billion, which was up 15.24% from $1.4 billion recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Current Assets ranged from a high of $1.6 billion in FY2024 and a low of $1.4 billion during FY2023.
  • For the 3-year period, Amneal Pharmaceuticals' Current Assets averaged around $1.5 billion, with its median value being $1.4 billion (2022).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Current Assets grew by 28.20% in 2020, and later decreased by 7.12% in 2022.
  • Amneal Pharmaceuticals' Current Assets (Yearly) stood at $1.6 billion in 2020, then fell by 2.03% to $1.5 billion in 2021, then decreased by 7.12% to $1.4 billion in 2022, then declined by 2.41% to $1.4 billion in 2023, then increased by 15.24% to $1.6 billion in 2024.